Showing results (241-250 of 296) with videos related to

Sort By:
Pageof 30
Gynecologic Oncology|December 22, 2007
Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)Hadassah Goldberg, Robert C Miller, Roxolyana Abdah-Bortnyak, et al.
Frontiers in Oncology|March 31, 2022
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry StudyMorgan Michalet, Karl Bordeau, Marie Cantaloube, et al.
The Lancet. Oncology|August 5, 2006
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer NetworkAurelius Omlin, Maurizio Amichetti, David Azria, et al.
Annales De Pathologie|December 17, 2011
[Locally advanced rectal cancer management: which role for the pathologist in 2011?]Frédéric Bibeau, Anne Rullier, Marie-Françoise Jourdan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2021
Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladderJonathan Khalifa, Stéphane Supiot, Géraldine Pignot, et al.
Critical Reviews in Oncology/Hematology|August 2, 2022
Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank MeetingCynthia Aristei, Yasemin Bölükbaşı, Orit Kaidar-Person, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2006
Genetic predictors of adverse radiotherapy effects: the Gene-PARE projectAlice Y Ho, David P Atencio, Sheila Peters, et al.
Cancers|January 8, 2023
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
Journal of Clinical Medicine|January 8, 2023
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical ResultsMorgan Michalet, Ons Bettaïeb, Samia Khalfi, et al.
Clinical Colorectal Cancer|July 18, 2019
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA StudyChristophe Borg, Georges Mantion, Frank Boudghène, et al.
Pageof 30